Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases

Kumamoto,Kensuke; Endo,Shungo; Isohata,Noriyuki; Nirei,Azuma; Nemoto,Daiki; Utano,Kenichi; Saito,Takuro; Togashi,Kazutomo

doi:10.3892/mco.2016.1096

Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases

Authors:
- Kensuke Kumamoto
- Shungo Endo
- Noriyuki Isohata
- Azuma Nirei
- Daiki Nemoto
- Kenichi Utano
- Takuro Saito
- Kazutomo Togashi
View Affiliations

Affiliations: Department of Coloproctology, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Fukushima 969-3492, Japan, Department of Surgery, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Fukushima 969-3492, Japan
Published online on: November 28, 2016 https://doi.org/10.3892/mco.2016.1096
Pages: 63-66

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A 70-year-old man who was diagnosed with unresectable advanced rectal cancer with multiple liver metastases, received oxaliplatin-based treatment with bevacizumab as first-line chemotherapy and irinotecan-based treatment with bevacizumab as second-line chemotherapy for a total of 17 months. The patient was treated with regorafenib (160 mg/day for 3 weeks) as third-line chemotherapy. Following completion of one course of regorafenib treatment, the patient complained of abdominal distension. Computed tomography (CT) examination identified liver atrophy and massive ascites, while no such symptoms were observed prior to the regorafenib treatment. Blood testing revealed increases in the aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels. The patient was admitted to the Aizu Medical Center (Aizuwakamatsu, Japan). Approximately 2,000 ml of ascitic fluid were aspirated daily for 1 week by abdominal puncture. The patient was administered oral diuretics, including 20 mg/day of furosemide and 25 mg/day of spironolactone. Albumin was administered to correct the albumin deficit. The levels of AST, ALT and ALP were decreased from the peak value reported on admission and the patient was discharged from our hospital 16 days following treatment initiation. The CT examination after 1 month revealed that the volume of the liver had been restored and the ascites had disappeared. Furthermore, almost all the liver metastases were reduced in size. The carcinoembryonic antigen level, which was elevated prior to regorafenib treatment, also decreased to normal.

View Figures

View References

1	Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY 73–4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 129:245–255. 2011. View Article : Google Scholar : PubMed/NCBI
2	Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al: CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI
3	Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, et al: CONCUR Investigators: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16:619–629. 2015. View Article : Google Scholar : PubMed/NCBI
4	Kim ST, Kim TW, Kim KP, Kim TY, Han SW, Lee JY, Lim SH, Lee MY, Kim H and Park YS: Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Res Treat. 47:790–795. 2015. View Article : Google Scholar : PubMed/NCBI
5	Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, et al: Randomized phase III trial of regorafenib in metastatic colorectal cancer: Analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 33:740–750. 2015. View Article : Google Scholar : PubMed/NCBI
6	Rey JB, Launay-Vacher V and Tournigand C: Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: An overview for pharmacists. Target Oncol. 10:199–213. 2015. View Article : Google Scholar : PubMed/NCBI
7	Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG and Tafaro A: Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery. J Cell Physiol. 228:292–297. 2013. View Article : Google Scholar : PubMed/NCBI
8	Ye L, Yang X, Guo E, Chen W, Lu L, Wang Y, Peng X, Yan T, Zhou F and Liu Z: Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One. 9:e966642014. View Article : Google Scholar : PubMed/NCBI
9	Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, et al: Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: A preliminary study. PLoS One. 7:e428752012. View Article : Google Scholar : PubMed/NCBI
10	Lee SL, Chang ED, Na SJ, Kim JS, An HJ, Ko YH and Won HS: Pseudocirrhosis of breast cancer metastases to the liver treated by chemotherapy. Cancer Res Treat. 46:98–103. 2014. View Article : Google Scholar : PubMed/NCBI
11	Jeong WK, Choi SY and Kim J: Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer. Clin Mol Hepatol. 19:190–194. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kang SP, Taddei T, McLennan B and Lacy J: Pseudocirrhosis in a pancreatic cancer patient with liver metastases: A case report of complete resolution of pseudocirrhosis with an early recognition and management. World J Gastroenterol. 14:1622–1624. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kobashigawa C, Nakamoto M, Hokama A, Hirata T, Kinjo F and Fujita J: Pseudocirrhosis in metastatic esophageal cancer. South Med J. 103:488–489. 2010. View Article : Google Scholar : PubMed/NCBI
14	Harry BL, Smith ML, Burton JR Jr, Dasari A, Eckhardt SG and Diamond JR: Medullary thyroid cancer and pseudocirrhosis: Case report and literature review. Curr Oncol. 19:e36–e41. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wanless IR: Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 11:787–797. 1990. View Article : Google Scholar : PubMed/NCBI
16	Ghabril M and Vuppalanchi R: Drug-induced nodular regenerative hyperplasia. Semin Liver Dis. 34:240–245. 2014. View Article : Google Scholar : PubMed/NCBI
17	Viganò L, Rubbia-Brandt L, De Rosa G, Majno P, Langella S, Toso C, Mentha G and Capussotti L: Nodular Regenerative Hyperplasia in Patients Undergoing Liver Resection for Colorectal Metastases After Chemotherapy: Risk Factors, Preoperative Assessment and Clinical Impact. Ann Surg Oncol. 22:4149–4157. 2015. View Article : Google Scholar : PubMed/NCBI